What is RNAC's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.21B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for RNAC?

P/E (TTM) is n/a and 52-week range is $5.60 to $11.00 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s RNAC figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for RNAC?

The company profile lists revenue (TTM) near $1M, net income (TTM) near $-12.44B, EPS (TTM) near $-5.87 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Cartesian Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Frederick, Maryland, US, 29.4M shares outstanding, ISIN US8162123025 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Cartesian Therapeutics Inc

$RNAC

Health Care · Biotechnology

IR Run Scenarios

$7.05

+3.45%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Cartesian Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in mRNA cell therapies for the treatment of autoimmune diseases. The company is headquartered in Frederick, Maryland and currently employs 75 full-time employees. The company went IPO on 2016-06-22. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. The Company’s lead asset, Descartes-08, is a chimeric antigen receptor T-cell therapy (CAR-T) entering Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-B-cell maturation antigen (BCMA) CAR-T being evaluated in a Phase 1 trial in patients with multiple myeloma. Descartes-08 is an autologous chimeric antigen receptor T-cell therapy product targeting B-cell maturation antigen in clinical development for generalized myasthenia gravis and systemic lupus erythematosus.

Employees

Website

www.cartesiantherapeutics.com/

IPO

2016-06-22

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)